SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022, after the U.S. financial markets close.
Read more at prnewswire.comhello world
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
